{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T10:33:07Z","timestamp":1780482787460,"version":"3.54.1"},"reference-count":28,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.clml.2021.01.017","type":"journal-article","created":{"date-parts":[[2021,2,23]],"date-time":"2021-02-23T03:26:28Z","timestamp":1614050788000},"page":"e569-e578","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Clinical and Molecular Attributes of Patients With BCR\/ABL1-negative Myeloproliferative Neoplasms in India: Real-world Data and Challenges"],"prefix":"10.1016","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2067-8567","authenticated-orcid":false,"given":"Suvir","family":"Singh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Komalpreet","family":"Kaur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davinder","family":"Paul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunal","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jagdeep","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8115-5439","authenticated-orcid":false,"given":"Vikram","family":"Narang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhavna","family":"Garg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neena","family":"Sood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barjinderjit","family":"Dhillon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2021.01.017_bib1","first-page":"121","article-title":"Myelofibrosis: clinicopathologic features, prognosis, and management","volume":"16","author":"O\u2019Sullivan","year":"2018","journal-title":"Clin Adv Hematol Oncol"},{"key":"10.1016\/j.clml.2021.01.017_bib2","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.01.017_bib3","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1002\/ajh.24221","article-title":"Myeloproliferative neoplasms: a decade of discoveries and treatment advances","volume":"91","author":"Tefferi","year":"2016","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2021.01.017_bib4","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1002\/ajh.24288","article-title":"Myeloproliferative neoplasms: morphology and clinical practice","volume":"91","author":"Barbui","year":"2016","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2021.01.017_bib5","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1182\/blood-2005-03-1320","article-title":"Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders","volume":"106","author":"Jones","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.01.017_bib6","doi-asserted-by":"crossref","DOI":"10.1177\/2040620719870052","article-title":"Updates in the management of polycythemia vera and essential thrombocythemia","volume":"10","author":"Bose","year":"2019","journal-title":"Ther Adv Hematol"},{"key":"10.1016\/j.clml.2021.01.017_bib7","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1038\/s41375-018-0107-z","article-title":"GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis","volume":"32","author":"Tefferi","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2021.01.017_bib8","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1002\/ajh.23585","article-title":"Masked polycythemia vera (mPV): results of an international study","volume":"89","author":"Barbui","year":"2014","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2021.01.017_bib9","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.beha.2014.07.004","article-title":"Essential thrombocythemia vs. early\/prefibrotic myelofibrosis: why does it matter","volume":"27","author":"Barosi","year":"2014","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.clml.2021.01.017_bib10","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/bjh.15562","article-title":"What is pre-fibrotic myelofibrosis and how should it be managed in 2018?","volume":"183","author":"Curto-Garcia","year":"2018","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2021.01.017_bib11","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1038\/leu.2013.163","article-title":"Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study","volume":"27","author":"Tefferi","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2021.01.017_bib12","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.mayocp.2011.11.001","article-title":"One thousand patients with primary myelofibrosis: the Mayo Clinic experience","volume":"87","author":"Tefferi","year":"2012","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.clml.2021.01.017_bib13","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1111\/ejh.13232","article-title":"Characteristics and outcomes of young adults with Philadelphia-negative myeloproliferative neoplasms","volume":"102","author":"Barzilai","year":"2019","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clml.2021.01.017_bib14","doi-asserted-by":"crossref","first-page":"3803","DOI":"10.1182\/blood-2013-09-527903","article-title":"Distinct clustering of symptomatic burden among myeloproliferative neoplasm patients: retrospective assessment in 1470 patients","volume":"123","author":"Geyer","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.01.017_bib15","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1182\/blood-2008-07-170449","article-title":"New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment","volume":"113","author":"Cervantes","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.01.017_bib16","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1309\/AJCPK7KGOWPHYWM0","article-title":"High percentage of JAK2 exon 12 mutation in Asian patients with polycythemia vera","volume":"134","author":"Yeh","year":"2010","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.clml.2021.01.017_bib17","doi-asserted-by":"crossref","first-page":"a034876","DOI":"10.1101\/cshperspect.a034876","article-title":"The molecular genetics of myeloproliferative neoplasms","volume":"10","author":"Marneth","year":"2020","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.clml.2021.01.017_bib18","first-page":"423","article-title":"Prevalence of JAK2 V617F mutation in Indian patients with chronic myeloproliferative disorders","volume":"132","author":"Sazawal","year":"2010","journal-title":"Indian J Med Res"},{"issue":"Suppl 1","key":"10.1016\/j.clml.2021.01.017_bib19","doi-asserted-by":"crossref","first-page":"i198","DOI":"10.1093\/ije\/dyv096.318","article-title":"Incidence rates of myeloproliferative neoplasms in India-a hospital-based study","volume":"44","author":"Varma","year":"2015","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.clml.2021.01.017_bib20","doi-asserted-by":"crossref","first-page":"35","DOI":"10.4103\/ijmpo.ijmpo_192_17","article-title":"Clinicopathological spectrum of BCR-ABL-negative myeloproliferative neoplasms with correlation with janus-associated kinase 2 mutation","volume":"40","author":"Dixith","year":"2019","journal-title":"Indian J Med Paediatric Oncol"},{"key":"10.1016\/j.clml.2021.01.017_bib21","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1111\/bjh.14762","article-title":"Impact of genotype on leukaemic transformation in polycythaemia vera and essential thrombocythaemia","volume":"178","author":"Alvarez-Larr\u00e1n","year":"2017","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2021.01.017_bib22","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1182\/asheducation-2018.1.110","article-title":"JAK2 (and other genes) be nimble with MPN diagnosis, prognosis, and therapy","volume":"2018","author":"Ciboddo","year":"2018","journal-title":"Hematology"},{"key":"10.1016\/j.clml.2021.01.017_bib23","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s00277-017-3193-5","article-title":"Non-driver mutations in patients with JAK2V617F-mutated polycythemia vera or essential thrombocythemia with long-term molecular follow-up","volume":"97","author":"Sen\u00edn","year":"2018","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2021.01.017_bib24","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1586\/17474086.2014.876898","article-title":"Cooperation between pathologists and clinicians allows a better diagnosis of Philadelphia chromosome-negative myeloproliferative neoplasms","volume":"7","author":"Gianelli","year":"2014","journal-title":"Exp Rev Hematol"},{"key":"10.1016\/j.clml.2021.01.017_bib25","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1002\/stem.2845","article-title":"Concise review: age-related clonal hematopoiesis: stem cells tempting the devil","volume":"36","author":"Busque","year":"2018","journal-title":"Stem Cells"},{"key":"10.1016\/j.clml.2021.01.017_bib26","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.mayocp.2018.08.022","article-title":"3023 Mayo Clinic patients with myeloproliferative neoplasms: risk-stratified comparison of survival and outcomes data among disease subgroups","volume":"94","author":"Szuber","year":"2019","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.clml.2021.01.017_bib27","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s11899-017-0399-5","article-title":"Approach to MPN symptom assessment","volume":"12","author":"Geyer","year":"2017","journal-title":"Curr Hematol Malig Rep"},{"key":"10.1016\/j.clml.2021.01.017_bib28","doi-asserted-by":"crossref","first-page":"321","DOI":"10.3389\/fonc.2019.00321","article-title":"The role of new technologies in myeloproliferative neoplasms","volume":"9","author":"Palumbo","year":"2019","journal-title":"Front Oncol"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265021000355?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265021000355?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:36:30Z","timestamp":1761870990000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265021000355"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":28,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["S2152265021000355"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2021.01.017","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical and Molecular Attributes of Patients With BCR\/ABL1-negative Myeloproliferative Neoplasms in India: Real-world Data and Challenges","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2021.01.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}